Alberta Securities Commission Rules In Favor Of Pembina/Inter Pipeline In Brookfield Litigation

Pembina Pipeline Corp. (PBA,PPL.TO) said that the Alberta Securities Commission or ASC has dismissed Brookfield's application to terminate Pembina's proposed plan of arrangement with Inter Pipeline Ltd. (IPL.TO). The Commission has upheld the break fee that may be paid by IPL to Pembina under that arrangement in certain circumstances.

The ASC also determined that Brookfield's total return swaps in connection with Brookfield's hostile take-over bid to acquire all of the outstanding common shares of IPL requires additional disclosure.

The ASC raised the minimum tender condition for Brookfield's unsolicited bid to 55 percent from 50 percent of the shares tendered by shareholders other than Brookfield and persons acting jointly or in concert with it.

Under the proposed Pembina Arrangement, Pembina would acquire all of the Inter Pipeline Shares on the basis of 0.5 of a Pembina common share in exchange for each Inter Pipeline Share.

Pembina and Inter Pipeline have urged their shareholders to reject the Brookfield bid and vote for the Pembina-Inter Pipeline deal.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT